6th Aug 2014 07:56
LONDON (Alliance News) - European pharmaceutical company Biofrontera AG said Wednesday that it has started selling its prescription drug Ameluz in Slovenia, the first of its Ameluz sales in the central eastern European region.
Biofrontera, which specialises in the development of dermatological drugs, medical devices and medical cosmetics for the treatment of skin diseases, listed on London's AIM market in June.
Its prescription drug Ameluz is for the treatment of actinic keratosis.
The company said in a statement Wednesday that Biofrontera Pharma GmbH is the official distributor in Slovenia, working in conjunction with its local partner PHA FARMED d.o.o., in Ljubljana, the capital of Slovenia.
Biofrontera shares were untraded Wednesday morning at EUR2.95 per share.
By Rowena Harris-Doughty; [email protected]; @rharrisdoughty
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
B8F.L